Skip to content

Hormones & growth

CJC-1295

Peptilex evidence grade ABCDEUpdated 19 Oct 2026 How grades work

Type: Long-acting GHRH analogue (with or without "DAC")
Main use or focus: Muscle gain, fat loss, recovery, "anti-aging"

Key studies from the book

Two randomized, placebo-controlled studies in healthy adults; growth hormone 2- to 10-fold higher for 6 days or more, IGF-1 1.5- to 3-fold higher for 9 to 11 days.
Teichman SL et al. – Journal of Clinical Endocrinology & Metabolism, 2006
Healthy men; natural growth hormone pulses preserved, IGF-1 up 45 percent.
Ionescu M, Frohman LA – Journal of Clinical Endocrinology & Metabolism, 2006

All key studies, risks and open questions are in the book.

Research at a glance

Publications by typePubMed, all years

All papers35

Human studies22

Animal studies only5

Randomized trials1

Meta-analyses & systematic reviews0

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Registered trials by phaseClinicalTrials.gov · name in study title

ongoing / startingcompleted / other

Phase 21

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Trial starts per yearClinicalTrials.gov · by start date (planned starts included)

2016

2018

2020

2022

2024

2026

Source: PubMed and ClinicalTrials.gov via the Peptilex study database

Go deeper

Full profile in the book

What it is, how it acts, the key studies, risks and open questions.

Peptilex – The Peptide Encyclopedia, book cover

Peptilex – The Peptide Encyclopedia

34 peptides – from semaglutide to BPC-157 – in one book
An evidence grade (A–E) and the key studies for every peptide
Where each one stands in 2026 – US, EU and Switzerland

Formats: Kindle · Paperback · Hardcover

Amazon store: amazon.com · Change store

Registered trials

ClinicalTrials.gov · name in study title · ongoing first

Study	Phase	Status	Participants	Start
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity NCT00267527ConjuChem	Phase 2	Stopped early	120	Dec 2005

Latest key papers

PubMed · newest first

2019
A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS
Animal studyTimms M et al. · Drug Testing and AnalysisPMID 30938069
2019
An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma
Animal studyTimms M et al. · Drug Testing and AnalysisPMID 30489688
2016
Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions
ReviewVan Hout MC et al. · Substance Use & MisusePMID 26771670
2006
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Animal studyAlba M et al. · American Journal of Physiology. Endocrinology and MetabolismPMID 16822960
2006
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Human RCTTeichman SL et al. · J Clin Endocrinol MetabPMID 16352683

Related peptides

ATesamorelin CSermorelin CIpamorelin CEGHRP-2, GHRP-6 & hexarelin CKisspeptin ABremelanotide

The Peptide Encyclopediaamazon.com